Evidence map›Paper›PMID 39406967›Full record

ArticleCell biochemistry and biophysics2025

The Anti-proliferative Effect, Apoptotic Induction, and Cell Cycle Arrest of Tetra Halo Ruthenate Nanocomposites in Different Human Cancer Cell Lines.

Mariam Fathy, Salwa M El-Hallouty, Ahmed S Mansour, Mohamed Fahmy, Nourhan Hassan, Emad M ElZayat

Abstract read
PubMed Publisher
In one paragraph

Article in Cell biochemistry and biophysics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mariam FathyZoology Department, Faculty of Science, Cairo University, Giza, Egypt.
Salwa M El-HalloutyDrug bioassay-cell culture laboratory, Pharmacognosy Department, Pharmaceutical and Drug Industries Division, National Research Centre, Dokki, Giza, 12622, Egypt.
Ahmed S MansourDepartment of Laser Applications in Meteorology, Photochemistry and Agriculture, National Institute of Laser Enhanced Sciences (NILES), Cairo University, Cairo, Egypt.
Mohamed FahmyApplied Surfactant Laboratory, Egyptian Petroleum Research Institute, Nasr City, Cairo, Egypt.
Nourhan HassanBiotechnology Department, Faculty of Science, Cairo University, Giza, 12613, Egypt.
Emad M ElZayatBiotechnology Department, Faculty of Science, Cairo University, Giza, 12613, Egypt. elzayatem@sci.cu.edu.eg.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemotherapy is the most common cancer treatment, and metallic anticancer compounds have generated increasing amounts of interest since the discovery of cisplatin. More recently, scientists have focused on ruthenium-based compounds as alternatives for platinum compounds, which seem like ideal therapeutic anticancer alternatives to platinum derivatives. The present study aims to assess whether one or more of three Ruthenium-based nanocomposites, namely Ru+Lysine+CTAB (RCTL), Ru+CTAB (RCT), and Ru+Lysine (RL) exhibit pronounced anti-proliferative properties against different cancer cells. Three Ruthenium nanocomposites have been synthesized by standard chemical methods and characterized by Dynamic light scattering (DLS) and Transmission electron microscopy (TEM). The cytotoxic effect of the three composites has been evaluated by MTT in-vitro assay for different human cancer cell lines, namely MCF7, HepG2, A549, and PC3 versus normal human skin cell line (BJ1). The molecular underlying mechanisms of cytotoxicity have been assessed via qRT-PCR for pro-apoptotic makers P53 and Casp-3, and anti-apoptotic marker Bcl-2 as well as flow cytometric analysis of the cell cycle. Among the 3 nanocomposites, RCTL gave the best sensitivity and cytotoxicity especially on HepG2 with IC

Indexed as

Antineoplastic AgentsApoptosisCell Cycle CheckpointsNanocompositesRutheniumCaspase 3Cell Line, TumorCell ProliferationHumansProto-Oncogene Proteins c-bcl-2Tumor Suppressor Protein p53Antineoplastic AgentsCaspase 3Proto-Oncogene Proteins c-bcl-2RutheniumTumor Suppressor Protein p53Anti-cancer activityApoptosisCell cycle arrestRT-qPCRRuthenium-based Nanocomposites

Identifiers

PMID39406967

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.